HOME >> MEDICINE >> NEWS
Chemical compound inhibits tumor growth, size in new mouse study

WASHINGTON, Aug. 30 A non-toxic chemical compound that prevents cancer cells from producing a critical membrane component has been shown to suppress tumor growth and tumor size in mice without unwanted side effects, according to researchers at the Childrens National Medical Center in Washington, D.C. The finding could lead to the development of safe and effective human cancer treatments that do not have the harsh side effects associated with chemotherapy and other traditional cancer-fighting strategies.

The compound, a carbohydrate known as OGT2378, blocks the production of an enzyme that cancer cells need to make gangliosides, molecules found in the membranes of most cells. When secreted by cancer cells, gangliosides suppress the immune system, alter the microenvironment surrounding these cells and promote the growth of new blood vessels necessary for tumor growth and survival.

"Cancer cells produce gangliosides at a much more rapid rate than normal cells. By interfering with this process we can stop a tumor from growing in a rather dramatic fashion without damaging the normal tissue surrounding it," says Stephan Ladisch, M.D., director of the Center for Cancer and Immunology Research at the Childrens Research Institute. His findings were presented today at the 230th national meeting of the American Chemical Society, the worlds largest scientific society.

Tumors in mice treated with OGT2378 were one-tenth the size of those in untreated mice. The results suggest that a drug or other treatment can modify tumors in such a way that the bodys own defenses are able to attack the cancerous cells and eliminate growth, apparently without harmful side effects, Ladisch says.

"Chemotherapy and radiation are limited by the fact that the body can only withstand so much toxic exposure," Ladisch says. "As far as we know thats not the case with these inhibitors of ganglioside production."

Although this approach doesnt
'"/>


30-Aug-2005


Page: 1 2

Related medicine news :

1. Chemical in brain acts like a fuel gauge
2. Chemical maps hint at drugs effects on schizophrenia
3. Chemical found in curry may help immune system clear amyloid plaques found in Alzheimers disease
4. Chemicals in curry and onions may help prevent colon cancer
5. Chemical in many air fresheners may reduce lung function
6. Chemical guidance of T cells leads to immunologic memory and long-term immunity
7. Chemical used in food containers disrupts brain development
8. Occupational and Environmental Exposures of Skin to Chemicals-2005
9. Chemical present in clear plastics can impair learning and cause disease
10. Chemical library aids in developing drug system for nerve damage
11. New oxidation methods streamline synthesis of important compounds

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Chemical compound inhibits tumor growth size new mouse study

(Date:5/20/2013)... When people have lap ... become a celebrity. New Jersey governor Chris Christie, ... report (“Chris Christie Says Lap Band Surgery Is ... surgery was not done so that he could ... as a former lap band patient. Simply put, ...
(Date:5/20/2013)... Fountain Valley, CA (PRWEB) May 20, 2013 ... few dental professionals certified and trained to use the ... surgery designed to treat patients with gum disease. ... already lost teeth due to gum disease restore the ... disease begins with the buildup of plaque and tartar ...
(Date:5/20/2013)... 20, 2013 Mombo from Comfort ... conference of the US Lactation Consultant Association (USLCA) May ... nurses, doctors and other health professionals. , The ... helping lactation professionals discover and learn about the latest ... the most popular nursing pillows, which new mothers use ...
(Date:5/20/2013)... According to a May 6, 2013 CBS News article, ... tanning salons in the US may soon have to ... to see cancer warnings on indoor tanning beds ... for the use of indoor tanning and sun beds. The ... increasingly common over the last few decades (Go to goo.gl/TCT6m). ...
(Date:5/20/2013)... According to a June 2009 Bloomberg article, it ... to approximately $3.6 billion dollars per year (i). ... that there 15 million incidents of medical harm each ... who receives any form of medical treatment should be ... defines malpractice as “a dereliction of professional duty or ...
Breaking Medicine News(10 mins):Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2
(Date:5/20/2013)... , May 20, 2013  Neuralstem, Inc. (NYSE ... , MD, PhD, principal investigator, presented updated Phase ... cell (NSI-566) trial in the treatment of amyotrophic lateral ... disease) at the neuro diabetes special medical symposium in ... a talk called "Recent Therapeutic Advances in Stem Cell ...
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/20/2013)... 20, 2013 With herbal medicines relied upon ... the U.S. Pharmacopeial Convention (USP) will provide freely available ... herbal ingredients used in these products. Today, USP proposes ... new Herbal Medicines Compendium ( HMC ) ... hmc.usp.org . HMC will provide ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
Cached News: